WAT WATERS CORP /DE/

BULLISH Impact: 8/10 8-K
Horizon weeks Filed May 5, 2026 Processed 1mo ago SEC 0001193125-26-204955
8-K Item 2.02: Earnings release
Latest settled — T+20d ⚠ clustered
WAT ▲ +8.51% at T+20d
LONG call ✓ call won +8.51% · α vs SPY +3.56% · entry $342.75 → $371.93
Next anchor: T+60d in 6w
Last close $355.53 (close Jun 12) · +3.73% from $342.75 entry
Entry anchored
May 5, 2026
via day open
T+1d
+1.98%
call +1.98% · α +0.59%
$349.53
settled 6w ago
T+5d
+2.76%
call +2.76% · α +0.78%
$352.21
settled 5w ago
T+20d
+8.51%
call +8.51% · α +3.56%
$371.93
settled 12d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Waters reported Q1 2026 total revenue of $1.267B, well above the $1.20B consensus, driven by $747M in organic revenue (up 13% as reported, 11% constant currency) and $520M from the newly acquired BDS business. Adjusted EPS of $2.70 grew 20% YoY, beating the $2.31 consensus by 16.9%. The company raised full-year 2026 adjusted EPS guidance to $14.40-$14.60 and organic constant currency growth to 6.5%-8.0%, signaling strong momentum from the acquisition and organic execution.

Key Financial Metrics

Guidance
$6.405B-$6.455B
raised
Free Cash Flow
-$42.0M

Actionable Insight

The strong beat and raised guidance confirm accelerating momentum from both organic growth and the transformative BDS acquisition. Watch for Q2 guidance of $2.95-$3.05 adjusted EPS (flat to +3.4% YoY) as the integration progresses; the stock should re-rate higher on the raised full-year outlook. Monitor free cash flow trajectory in coming quarters as working capital normalizes.

Key Facts

  • Total reported revenue of $1.267B exceeded the high end of guidance by $56M and consensus of $1.20B.
  • Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of guidance by 200 bps.
  • Adjusted EPS of $2.70 grew 20% YoY, beating consensus of $2.31 by 16.9%.
  • Biosciences and Diagnostic Solutions (BDS) contributed $520M in revenue since the Feb 9 acquisition close, $40M above guidance.
  • Full-year 2026 adjusted EPS guidance raised to $14.40-$14.60 (from $14.30-$14.50), representing 10%-11% YoY growth.
  • Full-year 2026 organic constant currency revenue growth guidance raised to 6.5%-8.0% (from 5.5%-7.0%).
  • GAAP diluted EPS was ($0.87) due to $251M in acquisition-related purchase accounting charges (intangibles amortization and inventory step-up).
  • Free cash flow was negative ($42M) in Q1 vs positive $234M in the prior year, impacted by working capital build and BDS integration.

Financial Impact

Adjusted EPS beat consensus by $0.39 (16.9%); total revenue beat consensus by ~$67M (5.6%); guidance raised for both revenue and EPS.

revenueepsguidancecashFlow

Risk Factors

  • Integration risk from the large BDS acquisition; $5.2B in debt on the balance sheet increases financial leverage.
  • GAAP losses from purchase accounting charges will persist through 2026, potentially confusing headline readers.
  • Q2 adjusted EPS guidance of $2.95-$3.05 implies only flat to +3.4% YoY growth, a deceleration from Q1's 20% growth.

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
57% bullish (28 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-204955
Document: d131836d8k.htm0001193125-26-204955
Document: 0001193125-26-204955-index-headers.html0001193125-26-204955
Document: 0001193125-26-204955-index.html0001193125-26-204955
Document: 0001193125-26-204955.txt0001193125-26-204955
8-K Data (Synthetic)0001193125-26-204955

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access